articl
present
overview
differ
strategi
sampl
prepar
identif
mass
spectrometri
ms
biomark
serum
andor
plasma
consid
effect
variabl
involv
sampl
collect
handl
storag
describ
differ
approach
remov
high
abund
protein
serumplasma
fraction
review
advantag
disadvantag
techniqu
centrifug
ultrafiltr
differ
format
solid
phase
extract
organ
solvent
extract
gel
capillari
electrophoresi
liquid
chromatographi
also
discuss
varieti
current
proteom
method
main
applic
biomarkerrel
studi
hand
biomark
describ
adkin
et
al
protein
undergo
chang
concentr
state
associ
biolog
process
diseas
current
use
routin
popul
screen
diseas
diagnosi
prognosi
monitor
therapi
predict
therapeut
respons
unfortun
biomark
suffer
low
sensit
specif
predict
valu
particularli
appli
rare
diseas
popul
screen
program
past
year
develop
implement
proteom
technolog
field
protein
biomark
discoveri
undergon
exponenti
growth
proteom
technolog
platform
center
implement
mass
spectrometri
conjunct
sever
analyt
techniqu
solid
phase
extract
chromatographi
electrophoresi
biomarkerrel
proteom
studi
carri
date
focus
identifi
particular
biomark
group
biomark
abl
distinguish
differ
state
given
diseas
discov
socal
proteom
pattern
diseas
diagnosi
observ
within
mass
spectra
semin
later
controversi
studi
gener
excit
use
proteom
pattern
tool
diseas
diagnosi
report
petricoin
et
al
studi
mass
spectra
proteom
pattern
serum
sampl
women
ovarian
cancer
healthi
match
control
acquir
use
selditof
ms
inher
throughput
proteom
pattern
technolog
enabl
analysi
hundr
clinic
sampl
per
day
howev
although
mass
spectrometr
pattern
may
use
seem
clear
know
ident
protein
marker
crucial
order
valid
biomark
describ
zolg
langen
bring
biomark
market
diagnost
tool
gener
involv
three
phase
discoveri
ii
prototyp
marker
develop
iii
product
develop
moreov
discoveri
phase
split
three
major
stage
identif
potenti
biomark
ii
priorit
identifi
biomark
iii
preliminari
valid
qualif
priorit
biomark
unfortun
studi
carri
far
deal
discoveri
phase
within
identif
potenti
biomark
seem
clear
much
effort
especi
valid
stage
need
biomark
actual
use
clinic
purpos
serum
plasma
potenti
contain
element
protein
produc
bodi
mani
studi
suggest
low
molecular
weight
lmw
proteinpeptid
plasma
serum
peptid
hormon
small
secret
protein
correl
patholog
condit
present
opportun
potenti
clinic
util
therapeut
intervent
diagnost
prognost
biomark
technic
challeng
analysi
serumplasma
proteom
serumplasma
protein
present
unequ
concentr
domin
serum
albumin
immunoglobulin
almost
total
serumplasma
protein
weight
mask
detect
protein
especi
low
abund
protein
without
fraction
complex
serum
plasma
overwhelm
import
biolog
inform
lost
background
nois
surprisingli
sampl
prepar
strategi
includ
preliminari
procedur
sampl
handl
storag
method
remov
high
abund
protein
fraction
approach
constitut
import
field
studi
scientist
involv
biomarkerrel
project
sampl
prepar
remain
one
time
consum
error
prone
aspect
analyt
chemistri
much
increasingli
recogn
import
area
special
field
standard
sampl
prepar
procedur
serumplasma
profil
therefor
critic
obtain
reliabl
biomark
especi
build
biomark
pattern
sinc
slight
chang
given
sampl
prepar
procedur
lead
differ
protein
profil
standard
given
procedur
involv
follow
action
feasibl
studi
examin
literatur
consult
expert
select
method
ii
interlaboratori
studi
use
select
method
refer
materi
result
chang
method
use
last
step
may
decid
upon
iii
valid
interlaboratori
studi
particip
laboratori
receiv
sampl
analysi
follow
strict
protocol
result
thu
obtain
lead
either
adopt
valid
protocol
restart
standard
process
reselect
method
light
outcom
fail
attempt
review
attempt
present
overview
state
art
sampl
prepar
serumplasma
protein
profil
biomark
identif
prior
ms
review
effect
variabl
involv
sampl
collect
handl
type
collect
tube
anticoagul
clot
incub
time
serum
plasma
separ
clot
blood
cell
respect
storag
condit
also
discuss
differ
strategi
use
remov
high
abund
protein
well
fraction
techniqu
use
either
gener
sever
fraction
select
obtain
particular
subset
proteinspeptid
although
great
impact
sampl
collect
handl
storag
sensit
select
reproduc
given
analysi
well
known
littl
done
address
effect
serumplasma
sampl
use
biomarkerrel
studi
studi
carri
show
sampl
procedur
greatest
effect
proteom
profil
handl
procedur
storag
condit
rel
minor
effect
howev
everyon
agre
standard
protocol
serumplasma
sampl
handl
storag
requir
sinc
issu
procedur
better
rather
use
standard
procedur
obtain
compar
reproduc
result
differ
laboratori
comment
differ
serum
plasma
influenc
composit
exert
type
collect
tube
anticoagul
use
use
plasma
sampl
clot
incub
time
separ
serum
plasma
clot
blood
cell
respect
storag
condit
plasma
liquid
compon
blood
blood
cell
suspend
plasma
largest
singl
compon
blood
compris
total
blood
volum
kind
hematolog
test
plasma
obtain
whole
blood
prevent
clot
anticoagul
citrat
heparin
ad
blood
immedi
obtain
sampl
centrifug
separ
plasma
blood
cell
mani
biochem
laboratori
test
plasma
blood
serum
use
interchang
serum
resembl
plasma
composit
lack
coagul
factor
obtain
let
blood
specimen
clot
prior
centrifug
purpos
serumsepar
tube
use
contain
inert
catalyst
glass
bead
powder
facilit
clot
well
portion
gel
densiti
design
sit
liquid
cellular
layer
tube
centrifug
make
separ
conveni
although
serum
prefer
mani
test
anticoagul
plasma
sometim
interfer
result
plasma
seem
stabl
serum
shown
mani
author
protein
profil
obtain
plasma
serum
differ
time
insuffici
inform
avail
decid
whether
serum
plasma
prefer
proteom
studi
biomark
discoveri
studi
use
serum
research
topic
requir
ideal
solut
would
use
although
would
complic
data
analysi
requir
longer
process
time
previou
studi
effect
blood
collect
mani
type
laboratori
analys
suggest
optim
standard
collect
tube
import
element
reliabl
analysi
serum
plasma
protein
commerci
avail
blood
collect
tube
contain
multipl
compon
may
appear
interf
confound
peak
ms
analysi
silicon
commonli
use
lubric
stopper
coat
intern
surfac
tube
polymer
surfact
polyvinylpyrrolidon
polyethelen
glycol
may
ad
influenc
surfac
wet
tube
may
also
contain
either
clot
inhibitor
activ
serum
separ
tube
contain
polymer
gel
sever
constitu
adjust
viscos
densiti
physic
properti
rubber
stopper
plastic
compris
tube
wall
may
also
shed
polym
drake
et
al
examin
shed
compon
sever
collect
tube
commonli
use
instead
use
serum
plasma
studi
carri
aqueou
salin
solut
simul
typic
contact
time
blood
compon
tube
collect
process
thu
avoid
potenti
confus
whether
observ
peak
repres
peak
deriv
tube
serumplasma
compon
studi
show
seven
tube
test
ad
polymer
compon
detect
multipl
signal
mz
rang
peak
could
potenti
complic
compromis
interpret
ms
spectra
low
molecular
weight
rang
especi
use
maldi
seldi
broad
spectrum
differ
compon
measur
singl
analysi
addit
shed
compon
tube
adsorpt
serumplasma
protein
tube
may
occur
differ
protein
profil
sampl
obtain
depend
kind
tube
use
actual
signific
differ
found
compar
redtop
tube
glass
tube
contain
preserv
anticoagul
tigertop
tube
also
known
serum
separ
tube
sst
differ
studi
order
use
plasma
sampl
clot
must
prevent
use
anticoagul
immedi
blood
collect
ad
sampl
although
usual
anticoagul
alreadi
collect
tube
anticoagul
use
prepar
plasma
sampl
inher
advantag
disadvantag
although
platelet
stabl
citrat
anticoagul
collect
tube
usual
contain
liquid
form
dilut
plasma
heparin
sampl
also
appear
rel
stabl
heparin
act
bind
enhanc
activ
antithrombin
iii
also
bind
signific
number
protein
edtatr
blood
slightli
less
stabl
longer
period
time
mark
chang
appear
elaps
time
centrifug
increas
activ
mani
proteas
requir
metal
chelat
action
edta
may
help
prevent
coagul
promin
chang
ms
protein
profil
observ
compar
differ
anticoagul
plasma
protein
profil
obtain
edta
treatment
diverg
obtain
citrat
heparin
treatment
may
due
fact
edta
caus
platelet
clump
aggreg
might
chang
protein
content
plasma
effect
clot
time
protein
profil
obtain
serum
incub
time
separ
plasma
blood
cell
extens
studi
hsieh
et
al
serum
plasma
sampl
obtain
blood
store
either
c
room
temperatur
h
clot
incub
time
respect
analyz
protein
profil
plasma
sampl
chang
time
lag
separ
plasma
blood
cell
increas
either
c
room
temperatur
although
protein
profil
obtain
condit
among
differ
individu
show
rel
consist
author
attribut
chang
observ
continu
metabol
blood
cell
alter
cell
membran
integr
result
continu
releas
metabolit
andor
releas
degrad
product
clot
chang
protein
profil
obtain
serum
sampl
also
observ
differ
clot
time
c
room
temperatur
result
consist
obtain
author
villanueva
et
al
observ
signific
differ
ms
proteinpeptid
peak
intens
depend
clot
time
sometim
intens
peak
diminish
clot
time
case
increas
author
explain
behavior
degrad
plasma
peptid
hand
formationaccumul
new
peptid
clot
process
effect
shortterm
storag
serum
plasma
storag
temperatur
studi
minim
chang
observ
sampl
store
room
temperatur
within
first
h
h
chang
becam
observ
h
particularli
peak
mz
rang
differ
becam
even
pronounc
h
serum
plasma
store
h
c
profil
quit
similar
howev
time
prolong
h
signific
chang
observ
longterm
storag
plasmaserum
sampl
major
differ
observ
c
use
liquid
nitrogen
howev
controversi
whether
freezethaw
cycl
may
alter
serumplasma
composit
repeat
freez
c
thaw
ice
serumplasma
sampl
time
detect
chang
observ
similar
result
report
author
noo
et
al
observ
small
consist
chang
protein
profil
increas
number
freezethaw
cycl
except
set
serum
sampl
thaw
room
temperatur
instead
c
howev
still
gener
believ
freezethaw
cycl
greatli
chang
serumplasma
composit
like
due
peptid
aggreg
precipit
adsorpt
surfac
fig
hsieh
et
al
point
discrep
could
attribut
variat
thaw
procedur
assay
method
sinc
influenc
freezethaw
measur
basi
whole
spectra
sever
select
peak
mention
previous
comprehens
analys
serum
plasma
proven
difficult
especi
low
molecular
weight
low
abund
protein
wide
rang
concentr
abund
protein
tabl
review
centrifug
ultrafiltr
varieti
membran
filtrat
centrifug
forc
liquid
semiperm
membran
suspend
solid
solut
high
molecular
weight
retain
liquid
low
molecular
weight
solut
pass
membran
depend
molecular
weight
cut
mwco
membran
use
simpl
techniqu
extens
use
remov
high
molecular
weight
speci
serumplasma
base
biomark
discoveri
clinic
diagnosi
sever
diseas
lung
tumor
ovarian
cancer
hepatocellular
carcinoma
etc
differ
mwco
membran
rang
kda
kda
variou
centrifug
speed
g
g
use
special
solvent
condit
requir
disrupt
proteinproteinpeptid
interact
lmw
compon
may
bound
albumin
larger
speci
releas
free
pass
membran
addit
acetonitril
dilut
serum
plasma
final
concentr
vv
shown
drastic
posit
effect
enrich
lmw
proteinpeptid
without
affect
abil
procedur
remov
larger
protein
increas
protein
content
ultrafiltr
observ
ad
acetonitril
final
concentr
howev
studi
georgiou
et
al
report
ultrafiltr
fail
remov
albumin
high
molecular
weight
protein
human
plasma
studi
ultrafiltr
conduct
g
point
tirumalai
et
al
possibl
high
centrifug
forc
integr
membran
may
compromis
thu
allow
high
molecular
weight
compon
albumin
pass
addit
nondilut
plasma
use
ultrafiltr
conduct
nondenatur
solvent
condit
base
result
seem
low
speed
centrifug
use
dilut
serum
plasma
use
denatur
condit
key
variabl
success
perform
plasmaserum
centrifug
ultrafiltr
remov
highli
abund
protein
togeth
enrich
lmw
proteinpeptid
solid
phase
extract
spe
separ
techniqu
use
solid
phase
isol
one
one
type
analyt
solut
spe
commonli
use
serumplasma
sampl
cleanup
step
remov
high
abund
protein
solid
phase
extract
column
probabl
approach
wide
use
deplet
high
abund
protein
serumplasma
wide
use
first
step
biomarkerrel
proteom
studi
differ
type
spe
column
base
ionexchang
metalchel
affin
ligand
dyeligand
bacteri
protein
antibodi
combin
use
sever
high
abund
protein
deplet
kit
market
compani
agil
genway
biotech
biorad
sigmaaldrich
amersham
bioscienc
pierc
other
differ
chromatographi
format
use
includ
column
cartridg
microcolumn
spin
column
deplet
strategi
base
dyeligand
ionexchang
protein
specif
comparison
biolog
affin
separ
base
antibodi
protein
peptid
nucleotid
lectin
etc
much
select
specif
target
protein
bacteri
protein
protein
g
specif
bind
fc
region
immunoglobulin
g
igg
success
use
specif
separ
igg
serum
plasma
antibodybas
column
primari
choic
provid
effici
select
reproduc
deplet
high
abund
protein
major
disadvantag
antibodybas
deplet
column
featur
inher
work
antibodi
name
rel
high
cost
low
sampl
capac
interest
method
guerrier
et
al
employ
unimod
multidimension
concept
rapidli
achiev
effect
fraction
human
serum
method
base
use
column
compos
superimpos
sequenc
sorbent
sampl
cross
differ
adsorb
layer
protein
within
subsequ
trap
accord
complementari
properti
sorbent
load
captur
achiev
sequenc
column
disassembl
column
contain
differ
complement
protein
elut
separ
singl
step
optim
elut
condit
compar
classic
singlechemistri
fraction
base
exampl
anionexchang
ph
stepwis
elut
new
propos
approach
show
much
lower
protein
overlap
fraction
therefor
greater
resolut
significantli
higher
sensit
low
abund
speci
also
found
evidenc
spike
trial
accord
studi
et
al
proteoextract
tm
albuminigg
remov
kit
select
reproduc
among
common
dispos
singleus
deplet
column
test
recent
method
base
mix
six
polyclon
antibodi
column
rapidli
effici
deplet
six
abund
protein
serum
plasma
singl
purif
step
develop
approach
abl
deplet
total
serum
protein
serumplasma
exampl
combin
dyeligand
affin
column
remov
albumin
protein
column
remov
ig
provid
deplet
total
serum
protein
multipl
affin
remov
system
mar
also
call
multipl
affin
remov
column
marc
commerci
agil
technolog
major
advantag
mar
antibodi
column
effici
deplet
six
highli
abund
protein
includ
differ
molecular
form
mani
proteolyt
product
protein
low
nonspecif
loss
protein
thu
provid
larger
number
detect
speci
complex
sampl
serum
plasma
exampl
echan
et
al
compar
differ
spe
column
show
extens
loss
occur
dyebas
affin
column
mar
column
lowest
loss
nontarget
protein
moreov
antibodi
rel
robust
protein
column
last
mani
purif
cycl
appropri
care
taken
minim
proteolysi
column
clog
shown
mar
system
also
work
effect
spin
column
format
allow
parallel
process
multipl
sampl
requir
complex
instrument
two
mar
column
also
use
tandem
increas
load
capac
l
plasma
although
mar
column
shown
best
spe
column
deplet
abund
protein
serumplasma
even
deplet
six
abund
protein
next
abund
one
rapidli
becom
problem
identifi
low
abund
protein
henc
ideal
highli
select
column
could
deplet
least
abund
protein
compris
total
serum
protein
content
would
desir
toward
end
new
column
contain
polyclon
immunoglobulin
yolk
igi
antibodi
seppro
tm
mix
spin
column
genway
biotech
may
promis
step
igi
antibodi
abund
protein
coval
coupl
microbead
use
pack
column
high
reproduc
mainten
separ
capac
multipl
cycl
observ
recycl
spin
column
time
caus
appar
loss
specif
capac
underli
chemic
principl
use
spe
disk
plate
high
abund
protein
remov
serumplasma
sampl
use
spe
column
differ
function
ionexchang
dyeligand
revers
phase
disk
use
main
advantag
associ
use
spe
disk
plate
increas
abil
autom
disk
plate
gener
use
plate
format
allow
simultan
process
elev
number
sampl
use
robot
also
common
use
differ
elutionwash
buffer
appli
sequenti
disk
order
assur
adsorb
proteinpeptid
elut
fraction
possibl
select
remov
larg
abund
protein
serum
precipit
simultan
often
unsuit
analyz
intact
protein
extract
peptid
low
molecular
weight
protein
use
organ
solvent
test
precipit
organ
solvent
presenc
ionpair
agent
dissoci
peptid
smaller
protein
larg
abund
protein
therebi
facilit
extract
shown
two
volum
acetonitril
ad
serumplasma
sampl
effici
precipit
larg
abund
protein
albumin
smaller
protein
peptid
stay
solut
subsequ
analyz
ms
chertov
et
al
appli
procedur
prepar
mous
serum
sampl
analysi
seldi
ms
show
signific
improv
mass
spectra
polypeptid
signal
present
seldi
ms
spectra
extract
materi
absent
spectra
total
serum
observ
peptid
serum
extract
crucial
detect
two
marker
lower
abund
serum
extract
tumor
bear
mice
extract
procedur
also
reproduc
analysi
aliquot
human
serum
maldi
ms
provid
practic
ident
spectra
extract
acetonitril
contain
trifluoroacet
acid
tfa
moreov
extract
materi
much
less
total
protein
make
easier
purifi
identifi
potenti
marker
due
high
complex
serumplasma
sampl
differ
fraction
strategi
use
either
gener
sever
fraction
gel
capillari
electrophoresi
liquid
chromatographi
select
obtain
particular
subset
proteinspeptid
common
featur
base
similar
affin
particular
solid
support
type
strategi
discuss
also
includ
strategi
applic
although
use
yet
specif
biomarkerrel
proteom
studi
show
potenti
futur
use
biomark
discoveri
see
tabl
previous
discuss
solid
phase
extract
commonli
use
remov
high
abund
protein
serumplasma
sampl
howev
spebas
strategi
also
use
isol
particular
fraction
proteinspeptid
within
origin
sampl
analyz
surfaceenhanc
laser
desorptionion
seldi
affinitybas
mass
spectrometr
method
combin
sampl
fraction
ms
analysi
seldi
util
stainless
steel
aluminumbas
support
chip
engin
chemic
hydrophil
hydrophob
preactiv
normalphas
immobil
metal
affin
cation
anion
biolog
antibodi
antigen
bind
fragment
scfv
dna
enzym
receptor
bait
surfac
mm
diamet
select
subset
protein
peptid
adsorb
one
key
aspect
lend
power
process
raw
fig
gener
strategi
acquisit
protein
pattern
seldi
serum
sampl
appli
protein
chip
contain
one
sever
possibl
adsorb
surfac
chemistri
seri
wash
step
applic
energyabsorb
molecul
mass
spectral
imag
speci
retain
protein
chip
surfac
acquir
bioinformat
softwar
use
discov
peak
within
mass
spectral
imag
indic
diseas
statu
healthi
diseaseaffect
patient
serum
acquir
reproduc
conrad
et
al
permiss
adi
biofluid
urin
synovi
fluid
nippl
fluid
aspir
hemodialysi
fluid
serumplasma
etc
tissu
directli
analyz
applic
chip
surfac
short
incub
period
unbound
protein
remov
surfac
use
wash
buffer
thu
protein
interact
chemistri
array
surfac
retain
analysi
wash
maldi
matrix
appli
array
final
step
acquir
ms
spectra
follow
bioinformat
analysi
fig
technolog
allow
sensit
highthroughput
protein
profil
rel
complex
biolog
specimen
multipl
surfac
employ
stepgradi
style
wash
procedur
singl
sampl
readili
dispers
mani
target
spot
limit
fraction
allow
detect
addit
protein
plasmaserum
increas
number
peak
hundr
rang
seldi
one
earliest
platform
use
find
proteom
pattern
diseas
diagnosi
sinc
first
studi
author
obtain
proteom
pattern
serum
earli
detect
ovarian
cancer
number
public
describ
use
technolog
increas
significantli
past
year
studi
petricoin
et
al
follow
report
claim
obtain
protein
pattern
abl
distinguish
patient
certain
diseas
prostat
breast
ovarian
renal
cancer
healthi
patient
sensit
specif
close
case
howev
almost
time
critic
shortcom
relat
use
seldi
especi
includ
reproduc
issu
build
protein
pattern
report
author
diamandi
point
discriminatori
peak
ie
peak
repres
molecul
appear
disappear
diseas
progress
whose
amount
differ
diseas
versu
healthi
patient
obtain
seldi
report
four
paper
studi
prostat
cancer
three
differ
research
group
differ
even
two
paper
publish
group
use
experiment
data
differ
analysi
tool
discrep
suggest
serumplasma
proteom
pattern
obtain
seldi
may
reproduc
discriminatori
peak
consist
within
group
among
group
investig
type
cancer
even
gener
analyt
method
dataset
furthermor
report
diagnost
sensit
specif
differ
substanti
among
four
report
anoth
phenomenon
associ
data
serum
protein
known
distinguish
patient
benign
condit
patient
malign
identifi
seldi
rais
seriou
question
analyt
sensit
human
proteom
organ
hupo
carri
interlaboratori
studi
eight
differ
laboratori
involv
analyz
serum
plasma
refer
specimen
use
seldi
order
answer
pertin
question
includ
whether
protein
detect
seldi
major
subset
plasmaserum
proteom
ie
informationrich
fraction
seldi
analysi
done
reproduc
dozen
hundr
sampl
singl
laboratori
across
sever
laboratori
larg
populationbas
studi
reliabl
perform
studi
show
fraction
proteom
observ
seldi
fact
abl
establish
differ
group
clear
differ
serum
plasma
plasma
type
found
use
seldi
platform
differ
consist
reproduc
found
laboratori
submit
qualifi
data
howev
also
becam
clear
stringent
step
must
taken
enabl
meaning
comparison
interlaboratori
data
contrast
rel
eas
accuraci
differenti
profil
carri
one
instrument
one
laboratori
origin
wide
use
seldi
ms
instrument
platform
acquir
proteom
pattern
proteinchip
tm
biomark
system
ii
pbsii
manufactur
ciphergen
inc
develop
area
research
signific
advanc
technolog
sinc
develop
exampl
use
highresolut
mass
spectromet
conrad
et
al
demonstr
increas
sensit
specif
ovarian
cancer
marker
serum
use
qstar
compar
convent
selditof
despit
extens
discuss
literatur
whether
use
seldi
ms
protein
pattern
discoveri
diseas
diagnosi
andor
prognosi
good
choic
fact
larg
number
research
chosen
platform
biomark
project
great
number
paper
publish
sinc
appli
import
group
diseas
studi
use
seldi
focus
cancer
includ
breast
prostat
ovarian
colorect
gastric
endometri
pancreat
head
neck
lung
cancer
neuroblastoma
hepatocellular
renal
cell
nasopharyng
carcinoma
metastat
pheochromocytoma
glioma
melanoma
bone
metastas
among
diseas
studi
use
techniqu
sever
acut
respiratori
syndrom
sar
acut
myocardi
infarct
ami
chronic
heart
diseas
ischem
hemorrhag
stroke
diabet
liver
cirrhosi
intraamniot
infect
rheumatoid
arthriti
sleepdisord
breath
children
african
trypanosomiasi
sleep
sick
arsen
lead
exposur
respiratori
diseas
alcohol
almost
studi
claim
provid
ms
pattern
abl
distinguish
subject
without
diseas
howev
seldim
provid
ident
biomark
possibl
know
group
mz
valu
compris
pattern
actual
correspond
molecul
directli
relat
diseas
studi
materialenhanc
laser
desorptionion
meldi
new
techniqu
use
variou
function
carrier
materi
direct
protein
profil
employ
maldim
instrument
approach
quit
similar
seldi
sinc
proteinfunction
beadssuspens
directli
appli
onto
malditarget
mix
appropri
matrix
solut
analyz
maldim
howev
meldi
use
particl
higher
surfac
area
spot
use
seldi
chip
allow
detect
larger
number
peptid
protein
within
broad
molecular
mass
rang
without
prior
albumin
immunoglobulin
deplet
elut
desalt
step
mandatori
msanalysi
techniqu
howev
differ
studi
shown
carrier
materi
care
chosen
assur
best
result
particl
certain
properti
ie
highli
porou
spheric
low
size
rang
effect
use
meldi
iminodiacet
acid
ida
cu
link
cellulos
silica
poli
glycidyl
methacrylategmadivinylbenzenedvb
particl
diamond
powder
test
carrier
materi
serum
protein
profil
spectra
record
materi
show
similar
serum
mass
fingerprint
minor
intens
differ
attribut
variat
result
sampl
prepar
suspens
applic
maldi
target
matrix
crystal
effect
detail
analysi
reproduc
robust
approach
recent
report
show
quit
reproduc
spectra
serum
sampl
analyz
differ
time
sever
week
either
cellulos
silica
particl
two
paramet
time
sampl
prepar
ms
analysi
temperatur
identifi
potenti
sourc
bia
comparison
spectra
obtain
celluloseserum
suspens
show
absenc
peptid
maldi
target
store
room
temperatur
h
analysi
compar
sampl
analyz
immedi
plate
spot
hand
sampl
prepar
c
yield
almost
ident
profil
differ
profil
sampl
prepar
c
latter
case
signaltonois
ratio
decreas
result
difficulti
distinguish
nois
true
peak
although
extens
studi
serumplasma
protein
profil
biomark
discoveri
report
use
approach
prostat
control
serum
sampl
analyz
first
attempt
demonstr
capabl
strategi
detect
andor
identif
new
biomark
ongo
develop
autom
meldi
techniqu
employ
liquid
handl
robot
devic
high
throughput
analysi
repres
potenti
key
step
toward
multiplex
serumplasma
protein
profil
biomark
discoveri
recent
decad
magnet
bead
emerg
promis
new
platform
biomed
applic
particularli
biosepar
function
magnet
bead
use
solid
phase
extract
specif
subset
molecul
liquid
natur
molecul
retain
depend
directli
kind
surfacederivat
bead
use
new
technolog
first
appli
serumplasma
proteom
profil
obtain
pattern
peptid
mass
distinguish
sera
brain
tumor
patient
sera
healthi
peopl
use
revers
phase
bead
gener
oper
protocol
origin
describ
villanueva
et
al
consist
bead
suspens
magnet
bead
pellet
resuspend
pipet
updown
autom
protocol
vortex
manual
ii
bind
measur
volum
bead
suspens
transfer
tube
contain
aliquot
serum
plasma
magnet
bead
sampl
mix
bead
pull
side
magnet
forc
supernat
remov
discard
iii
wash
wash
solut
ad
bead
pull
left
right
one
magnet
result
later
jar
motion
bead
pull
side
wash
solut
remov
iv
bead
pulldown
bead
resuspend
pull
tip
tube
magnet
posit
underneath
follow
care
remov
supernat
v
elut
minim
volum
elut
solvent
ad
bead
pellet
mix
bead
pull
side
eluat
collect
first
studi
use
magnet
bead
relat
proteom
profil
serumplasma
biomark
discoveri
use
mass
spectrometri
carri
bead
derivat
revers
phase
ligand
rel
success
trial
magnet
bead
product
line
expand
significantli
notabl
bruker
dalton
includ
revers
phase
bead
type
also
weak
anion
wax
weak
cation
wcx
exchang
bead
immobil
metal
affin
captur
imac
bead
copper
iron
variant
largeprotein
bead
allow
retent
protein
sever
kda
magnet
bead
includ
glycobead
offer
multipl
method
glycoprotein
enrich
includ
chemic
captur
lectincaptur
strategi
thu
allow
profil
glycosyl
peptid
protein
glycanstructur
inform
cancer
research
antibodycaptur
bead
specif
enrich
differ
protein
group
antigen
specif
even
specif
protein
thu
give
access
low
abund
protein
serumplasma
approach
intrins
sensit
surfac
captur
chip
seldi
sinc
spheric
particl
larger
combin
surfac
area
smalldiamet
spot
detect
polypeptid
kda
rang
singl
droplet
l
serum
almost
uniqu
peptid
larger
sampl
set
report
use
strategi
also
amen
robust
autom
thu
provid
scalabl
reproduc
approach
cost
clinprot
magnet
bead
array
quit
low
accord
bruker
dalton
thu
allow
larger
valid
studi
signific
problem
associ
technolog
report
later
studi
author
develop
strategi
found
differ
batch
bead
compani
provid
differ
result
fig
although
reproduc
profil
obtain
use
batch
bead
sampl
differ
day
fig
fact
constitut
major
reproduc
issu
potenti
batchdepend
differ
veri
fie
anyon
use
solid
phase
extract
profil
purpos
strategi
compat
kind
mass
spectromet
howev
studi
date
carri
use
malditof
ms
combin
solid
phase
extract
use
magnet
bead
maldi
analysi
led
differenti
protein
express
pattern
associ
diseas
like
asthma
thyroid
cancer
use
revers
phase
gastric
cancer
use
antibodyconjug
magnet
nanoparticl
among
other
new
method
base
select
isol
nlink
glycosyl
peptid
proteolysi
serum
protein
follow
analysi
complex
mixtur
deglycosyl
form
peptid
lcmsm
maldimsm
report
approach
found
power
method
analysi
serum
proteom
detect
protein
protein
pattern
distinguish
individu
differ
physiolog
state
well
known
cellular
glycosyl
profil
chang
significantli
oncogenesi
diseas
prostat
specif
antigen
psa
exampl
one
best
character
secret
glycoprotein
use
cancer
diagnost
select
isol
subset
peptid
signific
reduct
sampl
analysi
complex
achiev
two
level
first
reduct
total
number
peptid
due
fact
everi
serum
protein
averag
contain
nlink
glycosyl
site
second
reduct
pattern
complex
remov
oligosaccharid
contribut
significantli
peptid
pattern
heterogen
moreov
abund
serum
protein
constitut
almost
total
serum
protein
albumin
contain
nlink
glycosyl
motif
therefor
effect
transpar
analysi
addit
approach
select
peptid
constant
region
immunoglobulin
thu
dramat
reduc
number
immunoglobulinderiv
peptid
import
sinc
immunoglobulin
constitut
approxim
total
protein
mass
serum
compris
popul
estim
million
differ
molecul
howev
although
reduct
peptid
redund
benefici
achiev
higher
coverag
proteom
per
analysi
also
appar
lead
loss
potenti
import
inform
nonglycosyl
protein
miss
approach
believ
major
serumspecif
protein
glycosyl
intracellular
protein
typic
nonglycosyl
may
repres
rich
sourc
biomark
leak
serum
might
go
undetect
ii
avail
fewer
peptid
per
protein
may
increas
number
fals
posit
protein
identif
iii
approach
may
reveal
differ
protein
level
glycosyl
level
diseas
process
alter
protein
posttransl
modif
includ
proteolyt
process
detect
glycopeptid
level
iv
collaps
peptid
modifi
differ
oligosaccharid
structur
singl
signal
obscur
potenti
diseas
marker
due
alter
oligosaccharid
structur
method
base
conjug
serum
glycoprotein
resin
use
hydrazid
chemistri
propos
zhang
et
al
method
glycoprotein
oxid
carri
first
order
convert
cisdiol
group
carbohydr
aldehyd
aldehyd
group
react
hydrazid
group
immobil
resin
form
coval
hydrazon
bond
immobil
glycoprotein
proteolyz
solid
support
former
nglycopeptid
releas
solid
support
pngase
f
treatment
analyz
ms
also
possibl
isotop
label
glycosyl
peptid
releas
solid
support
order
allow
quantit
result
method
shown
reproduc
achiev
increas
analyt
depth
higher
throughput
compar
analysi
sampl
without
select
analyt
enrich
furthermor
author
demonstr
peptid
pattern
obtain
abl
distinguish
serum
sampl
mice
carcinomainduc
skin
cancer
sampl
genet
ident
untreat
mice
anoth
approach
report
recent
reli
upon
use
lectin
class
protein
found
plant
bacteria
fungi
anim
known
bind
specif
oligosaccharid
moieti
common
approach
use
lectin
captur
serum
glycoprotein
digest
serum
trypsin
isol
glycopeptid
one
lectin
link
support
resin
elut
deglycosyl
bound
peptid
pngase
drake
et
al
show
differ
lectin
bound
agaros
bead
confer
select
enrich
serum
glycoprotein
overlap
redund
captur
protein
serial
affin
captur
strategi
differ
lectin
use
tandem
increas
fraction
capabl
use
approach
fucosespecif
lectin
increas
level
fucosyl
glycoform
glycoprotein
serum
individu
hepatocellular
carcinoma
compar
serum
healthi
patient
observ
show
abil
strategi
find
diagnost
biomark
part
ongo
trend
aim
translat
potenti
nanotechnolog
proteom
applic
nanopor
silica
particl
filter
serumplasma
protein
goal
effect
harvest
plasma
lmw
protein
studi
silica
particl
silicon
wafer
glass
bead
test
act
carrier
proteinlik
mimet
enrich
low
molecular
weight
protein
within
plasmaserum
biolog
fluid
nanopor
silicon
wafer
use
select
deplet
serumplasma
fraction
protein
silica
particl
controlledpor
nanopor
glass
bead
use
harvest
distinct
subset
proteom
serumplasma
sampl
subsequ
elut
evalu
author
shown
characterist
fraction
depend
pore
size
materi
use
addit
pore
size
surfac
modif
carrier
protein
eg
albumin
immobil
strategi
must
test
improv
fraction
purif
interest
low
molecular
weight
speci
electrophoresi
movement
charg
particl
medium
use
electr
field
induc
electrod
proteom
electrophoresi
special
gel
electrophoresi
still
cornerston
separ
techniqu
complex
protein
mixtur
although
altern
base
chromatoghraphi
protein
array
advanc
complement
techniqu
gel
capillari
electrophoresi
use
serumplasma
fraction
biomark
discoveri
ms
analysi
gel
electrophoresi
refer
techniqu
molecul
forc
across
span
gel
motiv
electr
current
activ
electrod
either
end
gel
provid
drive
forc
properti
molecul
size
electr
charg
structur
etc
determin
rapidli
electr
field
move
gel
twodimension
gel
electrophoresi
wide
use
proteom
studi
due
separ
power
protein
initi
separ
accord
isoelectr
point
pi
first
dimens
follow
separ
second
dimens
accord
molecular
weight
result
array
spot
detect
differ
stain
procedur
resolut
sensit
increas
use
strategi
immobil
ph
gradient
abl
creat
complet
pictur
actual
protein
content
sampl
howev
applic
gel
electrophoresi
biomark
discoveri
studi
rare
due
fact
techniqu
well
suit
analyz
larg
seri
sampl
quit
work
intens
slow
also
complic
typic
abund
dynam
rang
issu
afflict
serumplasma
analys
therefor
sampl
usual
deplet
albumin
immunoglobulin
prior
use
gel
electrophoresi
protein
consid
relev
biomark
identifi
mostli
accord
standard
proteom
protocol
base
proteolyt
ingel
digest
ms
analysi
despit
problem
associ
use
gel
electrophoresi
mention
previous
number
group
perform
compar
studi
year
discov
potenti
biomark
use
follow
maldi
ms
analysi
potenti
biomark
acut
myeloid
leukemia
hepatocellular
carcinoma
liver
toxic
hypertrophi
breast
cancer
among
other
report
agaros
gel
success
use
identif
potenti
biomark
prostat
cancer
focus
high
molecular
weight
hmw
protein
rang
protein
previous
report
prostat
cancer
use
genom
convent
base
proteom
approach
found
potenti
biomark
also
use
complement
seldi
search
biomark
acut
renal
allograft
reject
superior
profil
protein
level
wide
molecular
weight
rang
seldi
faster
sensit
analysi
peptid
small
protein
kda
comunal
et
al
propos
approach
base
denglycosyl
polypeptid
present
serum
simplifi
serum
proteom
profil
obtain
sever
polypeptid
appar
denglycosyl
shown
correl
presenc
hepatocellular
carcinoma
although
result
preliminari
ident
put
biomark
yet
known
data
suggest
denglycosyl
offer
method
enhanc
resolut
serum
protein
profil
although
studi
describ
use
convent
stain
procedur
protein
detect
subtl
chang
may
observ
use
differenti
gel
electrophoresi
dige
dige
constitut
proteom
equival
gene
express
analysi
dna
microarray
even
minor
differ
protein
express
detect
across
multipl
sampl
simultan
statist
confid
comparison
spot
intens
use
dige
approach
decyd
softwar
object
approach
base
comparison
bright
gel
imag
obtain
convent
stain
dige
use
deplet
high
abund
protein
serum
immunoaffin
deplet
column
identif
potenti
biomark
pancreat
breast
cancer
introduc
techniqu
capillari
electrophoresi
ce
design
separ
molecular
speci
base
size
charg
ratio
insid
small
capillari
innerdiamet
glass
silica
materi
fill
electrolyt
isoelectr
focus
ief
gel
electrophoresi
occur
within
capillari
ce
use
proteom
analyz
fraction
sampl
ms
analysi
high
resolut
ce
nanolit
sampl
volum
use
especi
advantag
serial
fraction
small
clinic
sampl
howev
number
actual
molecul
low
abund
protein
present
minut
sampl
need
kept
mind
without
prior
concentr
enrich
step
protein
peptid
low
concentr
may
entir
overlook
probabl
reason
studi
biomark
discoveri
use
cem
carri
urin
serumplasma
sampl
centrifug
ultrafiltr
use
prior
ce
remov
high
abund
protein
serumplasma
sinc
larg
protein
fairli
insolubl
would
result
appear
precipit
capillari
kaiser
et
al
detect
approxim
polypeptid
molecular
weight
da
plasma
ultrafiltr
also
approxim
compon
detect
use
autom
cem
approach
author
analyz
low
molecular
weight
peptid
serum
ultrafiltr
use
cem
method
incorpor
transient
isotachophoresi
inlin
preconcentr
sheathless
cem
electrospray
interfac
anoth
promis
approach
plasma
sampl
directli
inject
ce
capillari
without
sampl
pretreat
base
use
fuse
silica
capillari
coat
polybren
avoid
hydrophob
interact
capillari
wall
obtain
strong
revers
electroosmot
flow
eof
use
anod
separ
protein
migrat
eof
lower
posit
charg
protein
background
acet
acidbas
electrolyt
enter
detector
first
approach
provid
two
advantag
protein
complet
desalt
small
cation
migrat
direct
never
reach
detector
modifi
protein
glycosyl
form
separ
nonmodifi
form
lower
posit
charg
due
nonchargebear
group
neg
charg
modif
smaller
modifi
glycosyl
protein
separ
predomin
serum
protein
albumin
high
resolut
high
mass
accuraci
provid
modern
mass
spectrometri
technolog
suitabl
tent
identif
protein
monitor
mass
chang
level
intact
protein
diagnost
purpos
howev
far
know
biomark
discoveri
studi
report
use
approach
chromatograph
process
defin
separ
techniqu
involv
masstransf
stationari
mobil
phase
liquid
chromatographi
lc
wide
use
mode
analyt
chromatographi
use
liquid
mobil
phase
separ
compon
mixtur
compon
analyt
present
liquid
phase
dissolv
solvent
forc
flow
chromatograph
column
usual
high
pressur
hplc
column
mixtur
resolv
compon
degre
resolut
depend
extent
interact
solut
compon
stationari
phase
defin
immobil
pack
materi
column
interact
solut
mobil
stationari
phase
manipul
differ
choic
solvent
stationari
phase
result
lc
acquir
high
degre
versatil
found
chromatograph
system
abil
easili
separ
wide
varieti
chemic
mixtur
import
mention
although
principl
liquid
chromatographi
solid
phase
extract
similar
two
techniqu
often
confus
especi
use
solid
phase
extract
column
use
differ
purpos
serumplasma
treatment
spe
commonli
use
select
extract
either
undesir
high
abund
protein
cleanuppurif
specif
subset
protein
similar
characterist
glycoprotein
captur
strategi
describ
lc
separationfraction
techniqu
mani
serumplasma
fraction
gener
sever
spe
devic
spe
disk
plate
mar
affin
column
spe
column
connect
seri
provid
fraction
sampl
howev
separ
obtain
typic
less
fraction
low
compar
lc
resolut
greater
number
fraction
collect
limit
time
chromatograph
run
carri
also
import
differ
two
techniqu
oper
protocol
solid
sorbent
use
particl
size
especi
high
pressur
liquid
chromatographi
hplc
lc
combin
ms
primarili
perform
revers
phase
mode
analysi
peptid
natur
sourc
gener
proteolyt
digest
larger
protein
sinc
mobil
phase
directli
compat
requir
ioniz
atmospher
pressur
case
serumplasma
sampl
process
biomark
discoveri
lc
use
last
step
separ
peptid
immedi
ms
analysi
use
almost
sampl
prepar
techniqu
describ
main
fraction
approach
serumplasma
proteinspeptid
latter
case
multidimension
lc
system
usual
chosen
separ
serumplasma
sampl
differ
fraction
base
differ
principl
pi
hydrophob
thu
decreas
complex
sampl
subsequ
increas
probabl
identifi
biomark
lower
concentr
interest
studi
focus
lc
fraction
approach
serumplasma
sampl
sinc
use
lcm
last
step
identif
protein
wide
use
mani
kind
proteom
studi
requir
littl
innov
modif
use
biomarkerrel
studi
applic
lcm
biomark
discoveri
yet
widespread
partli
method
gener
larg
highli
complex
data
set
requir
power
algorithm
softwar
tool
handl
analyz
howev
attempt
carri
recent
although
alway
focus
biomark
discoveri
low
abund
protein
observ
serumplasma
proteom
investig
suggest
lcm
promis
platform
biomark
discoveri
protein
fraction
base
use
weak
anionexchang
wax
weak
cation
exchang
wcx
column
connect
seri
use
investig
mous
serum
proteom
load
serum
sampl
column
disconnect
captur
protein
elut
two
column
use
multistep
salt
gradient
collect
fraction
everi
minut
fraction
uniqu
protein
identifi
uniqu
peptid
protein
function
class
local
detect
numer
low
abund
protein
identifi
without
need
prior
remov
albumin
ig
analysi
establish
basi
detect
potenti
biomark
mous
model
determin
presenc
absenc
variou
molecular
speci
control
experiment
anim
similar
strategi
base
use
immunoaffin
chromatographi
remov
abund
serum
protein
follow
sequenti
anionexchang
sizeexclus
chromatographi
use
studi
human
serum
proteom
approach
combin
succeed
resolv
approxim
distinct
protein
includ
protein
present
serum
ng
ml
concentr
cathepsin
peptid
hormon
lc
often
unsuit
analyz
intact
protein
sinc
protein
tend
denatur
revers
phase
condit
low
ph
high
organ
solvent
concentr
make
quantit
elut
rather
difficult
howev
qin
et
al
use
beckman
coulter
proteomelab
pf
hplc
system
separ
serum
protein
anion
displac
lc
serum
fraction
collect
ph
interv
resolv
dige
serum
sampl
patient
prostat
cancer
patient
benign
prostat
hyperplasia
bph
studi
chromatofocus
appear
reliabl
reproduc
method
separ
protein
peptid
serum
protein
recov
fraction
ph
fig
profil
obtain
abl
distinguish
bph
prostat
cancer
reproduc
serum
fraction
approach
report
quit
good
signific
differ
chromatogram
differ
sampl
thu
demonstr
potenti
chromatofocus
reproduc
separ
desir
popul
serumplasma
protein
basi
pi
moreov
compar
profil
obtain
fraction
serum
profil
unfraction
serum
demonstr
total
uniqu
protein
identifi
follow
fraction
especi
import
presenc
sever
low
abund
protein
fraction
sampl
also
appli
make
compar
proteom
analys
plasma
sampl
individu
prior
h
lipopolysaccharid
lp
administr
use
strong
cation
exchang
scx
chromatographi
column
coupl
offlin
reversephas
column
total
protein
observ
significantli
increas
concentr
follow
lp
administr
includ
sever
known
inflammatori
respons
acutephas
mediat
thu
constitut
potenti
biomark
inflammatori
respons
sheng
et
al
also
use
commerci
instrument
beckman
coulter
separ
serum
protein
first
dimens
use
chromatofocus
follow
inlin
revers
phase
chromatographi
second
dimens
therebi
separ
intact
protein
base
pi
hydrophob
system
success
identifi
high
low
abund
protein
addit
isopropanol
first
dimens
buffer
enhanc
elut
protein
near
theoret
pi
author
report
nonredund
serum
protein
exclud
immunoglobin
albumin
consid
minimum
two
peptid
match
accept
mascot
score
unambigu
identifi
identifi
previous
serum
discuss
mani
differ
strategi
use
sampl
prepar
serumplasma
biomark
discoveri
use
mass
spectrometri
well
establish
approach
gel
electrophoresi
ultrafiltr
rel
new
strategi
glycoproteinglycopeptid
captur
use
nanopor
susbtrat
attempt
present
advantag
shortcom
well
mani
applic
report
far
biomarkerrel
proteom
studi
demonstr
larg
number
paper
publish
past
year
discoveri
rate
potenti
biomark
drug
target
alreadi
greatli
exceed
rate
preliminari
valid
gap
expect
increas
henc
one
first
step
requir
standard
sampl
prepar
protocol
order
obtain
reproduc
result
laboratori
lead
establish
potenti
biomark
valid
test
clinic
purpos
investig
especi
need
new
sampl
prepar
strategi
alreadi
provid
particularli
promis
result
multipl
affin
remov
system
multidimension
liquid
chromatographi
use
nanopor
solid
phase
